This article first appeared on GuruFocus .
Release Date: August 06, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
TriSalus Life Sciences Inc ( NASDAQ:TLSI ) received a new CMS G-code that extends TriNav reimbursement to office-based labs (OBLs), significantly expanding its market access and addressing a growing site-of-care trend.
-
The company is reiterating its full-year 2026 revenue guidance of $54 million to $57 million, reflecting 19% to 26% growth, and expects sequential improvement in Q3 and a stronger Q4.
-
Gross margin improved to 86.8% in Q2 2026, up from 83.9% in the prior year period, driven by lower average unit costs and continuous manufacturing improvements.
-
The company has a robust clinical pipeline with 11 active studies across 27 sites, including the completed PETER study submitted for publication and the PREDICT study actively enrolling, which could serve as future commercial catalysts.
-
The new G-code is expected to be a meaningful accelerant for the uterine artery embolization (UAE) indication, which is increasingly performed in OBL settings, removing a historical reimbursement barrier.
-
The company ended Q2 with approximately $46.3 million in cash, which management believes fully funds its strategic growth plan.
Negative Points
-
Q2 2026 revenue growth was modest at only 1.7% year-over-year ($11.4 million vs. $11.2 million), which is below the pace needed to hit the high end of the annual guidance.
-
Adjusted EBITDA loss widened to approximately $7.1 million in Q2 2026, up from $5.3 million in the prior year period, due to heavy investment in the expanded sales force.
-
Sales and marketing expenses surged to $11.4 million in Q2 2026, up from $7.2 million in the prior year period, reflecting elevated costs from recruiting, onboarding, and training new reps.
-
The FDA's review of the TriNav Advance 510(k) clearance is running past the MDUFA goal date, creating uncertainty about the timing of this key product launch.
-
The company's pancreatic strategy is under review due to significant changes in the treatment landscape, and the nelatolimod Phase I data readout is not expected until the second half of 2026, leaving a key pipeline asset in limbo.
-
The company is still in the early innings of its expanded commercial footprint, and while reps are ramping, the full productivity contribution is not expected until the back half of the year, leaving near-term growth dependent on execution.
Q & A Highlights
Q: Regarding the new office-based lab (OBL) reimbursement, which new indications could be most impactful, and when might you allocate more sales and marketing resources to capitalize on this? A: Mary Zella, President and CEO, explained that the CMS G-code extends TriNav reimbursement into OBLs, a setting where liver embolization procedures are increasingly migrating due to shorter wait times and flexible scheduling. Beyond liver, this opens opportunities in uterine artery embolization (UAE), prostate artery embolization, and genicular artery embolization, which are commonly performed in OBLs. The company is currently planning its strategy, noting the G-code arrived earlier than anticipated, and sees UAE as an early beneficiary by removing historical reimbursement barriers.
Q: Can you provide more detail on the productivity metrics and launch trajectory of the new sales representatives hired in the first quarter, and how impactful they can be in Q3 and Q4? A: Mary Zella stated that the sales force expansion began in February, with all new reps hired by April. With two quarters under their belts, their contributions are increasing substantially in the back half of the year. The company is excited about the caliber of talent attracted, with several reps exceeding internal metrics. Q2 results came in exactly on their internal operational model, and they feel confident about the growth trajectory for Q3 and Q4.
Q: Where are the overlapping call points between the current liver market and the adjacent markets you are expanding into, and can the current sales force leverage its liver work for these new indications? A: Mary Zella noted that interventional radiologists often work across both hospital settings and OBLs, with the same physicians performing procedures in both. The current sales force can handle the majority of this overlap initially, as the call points are largely the same. Dr. Richard Marshall, Chief Medical Officer, added that most interventional radiologists have broad practice diversity, performing Y90, TACE, and UAE, so the call point is identical. He cited UAE as an example where physicians using TriNav in the liver began using it for UAE, driving the company's investment in that indication.
Q: What is the significance of the CMS G-code for TriNav reimbursement in OBLs, and how does it expand the commercial opportunity? A: Mary Zella highlighted that the G-code is a seminal moment for TriSalus, extending reimbursement into the physician office setting (OBL). This expands patient access to pressure-enabled drug delivery (PEDD) regardless of treatment site, addressing the migration of liver cancer treatments from hospitals to OBLs. The company holds two unique HCPCS codes for HOPD and ASC settings, and this new code removes the reimbursement barrier for OBLs, which is particularly impactful for UAE and other embolization procedures.
Q: Can you provide an update on the clinical trial progress and evidence generation for TriNav? A: Mary Zella reported 11 active studies across 27 clinical sites, with data from over 400 patients treated with TriNav. The PETER study at Massachusetts General Hospital has been submitted for publication, and the TRIPI 90 study at MD Anderson is in data review. The PREDICT study at MD Anderson is actively enrolling, and the PRESSURE trial at Stanford will launch in Q3. New studies include a prospective trial to prove TriNav superiority over microcatheters in liver metastases and a multicenter neuroendocrine tumor study with the University of Pennsylvania.
Q: What is the status of the TriNav Advance 510(k) clearance with the FDA? A: Mary Zella stated that the company continues to anticipate near-term 510(k) clearance for TriNav Advance, which will expand liver market access by extending PEDD to small distal vessels via microcatheters. The review is running past the MAUFA goal, but the company remains in close dialogue with the FDA and hopes to receive clearance soon.
Q: What are the financial highlights for Q2 2026, and what is the full-year guidance? A: David Patience, CFO, reported Q2 revenue of $11.4 million, up 1.7% year-over-year, with gross margin improving to 86.8%. R&D expenses decreased to $3.1 million, while sales and marketing expenses increased to $11.4 million due to the commercial expansion. Adjusted EBITDA loss was $7.1 million, and the company ended the quarter with $46.3 million in cash. Full-year 2026 revenue guidance is reiterated at $54 million to $57 million, reflecting 19% to 26% growth, with sequential improvement expected from Q2 to Q3 and a stronger Q4.
Q: Can you elaborate on the real-world evidence study and its implications for TriNav adoption? A: Mary Zella highlighted a webinar featuring a real-world outcome study evaluating over 300 million patient lives, including 16,210 embolizations, with 1,200 patients compared using sophisticated matching. The data showed TriNav was used in the most challenging patients with high disease burden and complex anatomy, yet demonstrated clinical benefit. The HEOR data showed average cost savings of $7,700 in certain procedures, which serves to validate the platform and catalyze adoption.
Q: What is the progress on the emerging indications of uterine, thyroid, and genicular artery embolization? A: Mary Zella reported that the UAE expanded study is enrolling well toward a 50-patient target, with a prospective trial design in progress. The PROTECT registry for thyroid artery embolization has achieved the enrollment cutoff for interim analysis, with first multicenter US data expected in Q1 2027. For genicular artery embolization, the pilot registry has concluded, and the company is advancing a formal clinical trial design.
Q: What is the update on the nelatolimod and pancreatic programs? A: Mary Zella stated that the company remains on track to deliver the consolidated PERIO Phase I data readout for nelatolimod in the second half of 2026. Regarding the broader pancreatic strategy, significant changes in the pancreatic cancer treatment landscape are being evaluated, and an update will be provided after the analysis is complete.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
